|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-1-5
|
|
pubmed:abstractText |
A number of recent studies have shown that human polymorphisms near the IL28B type III interferon (IFN?) gene influence the response to peg-interferon plus ribavirin combination therapy for infection with chronic hepatitis C virus (HCV). Viral polymorphisms, including substitutions within the HCV core and NS5A proteins, have also been shown to influence treatment outcome, but it is not known whether these factors act independently of the IL28B polymorphism or if they reflect the same or a different underlying mechanism. Multiple logistic regression was used to determine whether host and viral polymorphisms independently predict sustained virological response (SVR).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents,
http://linkedlifedata.com/resource/pubmed/chemical/IL28B protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukins,
http://linkedlifedata.com/resource/pubmed/chemical/Polyethylene Glycols,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Ribavirin,
http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2b,
http://linkedlifedata.com/resource/pubmed/chemical/peginterferon alfa-2b
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1468-3288
|
|
pubmed:author |
pubmed-author:AbeHiromiH,
pubmed-author:AkutaNorioN,
pubmed-author:ChayamaKazuakiK,
pubmed-author:HayesC NelsonCN,
pubmed-author:ImamuraMichioM,
pubmed-author:KamataniNaoyukiN,
pubmed-author:KobayashiMarikoM,
pubmed-author:KumadaHiromitsuH,
pubmed-author:MikiDaikiD,
pubmed-author:NakamuraYusukeY,
pubmed-author:OchiHidenoriH,
pubmed-author:SuzukiFumitakaF
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
60
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
261-7
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21068134-Aged,
pubmed-meshheading:21068134-Amino Acid Substitution,
pubmed-meshheading:21068134-Antiviral Agents,
pubmed-meshheading:21068134-Drug Therapy, Combination,
pubmed-meshheading:21068134-Female,
pubmed-meshheading:21068134-Hepacivirus,
pubmed-meshheading:21068134-Hepatitis C, Chronic,
pubmed-meshheading:21068134-Humans,
pubmed-meshheading:21068134-Interferon-alpha,
pubmed-meshheading:21068134-Interleukins,
pubmed-meshheading:21068134-Male,
pubmed-meshheading:21068134-Middle Aged,
pubmed-meshheading:21068134-Polyethylene Glycols,
pubmed-meshheading:21068134-Polymorphism, Single Nucleotide,
pubmed-meshheading:21068134-Prognosis,
pubmed-meshheading:21068134-RNA, Viral,
pubmed-meshheading:21068134-Recombinant Proteins,
pubmed-meshheading:21068134-Ribavirin,
pubmed-meshheading:21068134-Treatment Outcome,
pubmed-meshheading:21068134-Viral Load
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.
|
|
pubmed:affiliation |
Laboratory for Digestive Diseases, Center for Genomic Medicine, RIKEN, Hiroshima, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
